IDIA.SW Stock Today: FY2025 Revenue Doubles; Loss Narrows — February 26

Idorsia stock drew Swiss investor attention on 26 February as the biotech reported FY2025 results. Swiss biotech Idorsia (IDIA.SW) doubled revenue to CHF 221m from CHF 113m, with Quviviq sales at CHF 134m. Net loss narrowed to CHF -112m and operating loss to CHF -33m. Shares were little changed near CHF 3.75. Management outlined Idorsia 2026 guidance, aiming for CHF 200m Quviviq sales while still expecting about CHF -160m in operating loss during ongoing restructuring under new CEO Srishti Gupta.

FY2025 Results at a Glance

Idorsia earnings 2025 showed revenue of CHF 221m, up from CHF 113m, driven largely by Quviviq sales of CHF 134m. The stronger top line reflects steadier insomnia demand and improved commercial execution. Management reiterated a focus on core assets while scaling back lower-priority spend. Figures are consistent with Swiss press coverage of the results source.

Losses narrowed as costs fell. The full-year net loss improved to CHF -112m, while operating loss tightened to CHF -33m. The company credited lower R&D and SG&A after previous restructurings. Investors will watch if this trajectory continues through 2026 as the group prioritizes Quviviq and tightens spending on late-stage programs.

Idorsia stock held near CHF 3.75 on the day, reflecting a “wait-and-see” stance. The market welcomed better losses but wants proof of sustainable growth. With a market cap around CHF 0.75bn, sentiment now hinges on prescription momentum and cost control, rather than pipeline optionality alone.

What the 2026 Guidance Signals

Management’s Idorsia 2026 guidance targets CHF 200m in Quviviq sales, up from CHF 134m in 2025. That implies a higher run-rate and broader adoption. Delivery will depend on prescriber uptake, patient adherence, and market access progress in key regions. Any co-promotion or partnership updates could also influence the path to that figure.

Despite stricter spending, the company still guides for an operating loss of about CHF -160m in 2026. Leadership under CEO Srishti Gupta is pressing ahead with deeper restructuring to improve efficiency, including staff reductions reported in Switzerland source. The balance between growth investment and cash discipline remains central.

A larger operating loss target suggests continued cash burn in 2026, even if working capital improves. We think progress on non-dilutive funding, milestone receipts, or portfolio pruning would support runway. Clear quarterly updates on spend, inventory, and receivables could help investors gauge whether losses are tracking toward a steadier level.

Quviviq Sales: Key Driver to Watch

Quviviq sales reached CHF 134m in 2025. Growth in 2026 can come from more prescribers, better patient persistence, and broader reimbursement. Educational outreach to primary care and sleep specialists may lift awareness. Direct-to-patient materials and digital tools can also support adherence, which is vital for recurring revenue in chronic insomnia.

Investors should track new and repeat prescriptions, net price trends, and any reimbursement wins. Watch marketing spend versus sales growth to judge productivity. Quarterly commentary on conversion from trials to maintained therapy will matter. Any signal of faster refill rates would support the case for higher Quviviq sales this year.

Key risks include competition from generics and branded rivals, pricing pressure, and slower-than-expected prescriber adoption. If marketing cuts go too far, demand growth could stall. Supply chain or inventory swings may also affect reported sales timing. These risks can keep Idorsia stock sensitive to each quarterly update.

Valuation and Technical Snapshot

At around CHF 3.75, Idorsia stock implies a market cap near CHF 0.75bn. On trailing metrics, EPS is about CHF -0.62, the P/S ratio sits near 3.22, and EV/S is about 8.38. With negative earnings, traditional PE is not useful. The setup argues that execution on Quviviq must lead sentiment rather than valuation multiples.

Near-term technicals are neutral. RSI is around 49, signaling neither overbought nor oversold. ADX near 15 indicates a weak trend. Bollinger Bands sit roughly at CHF 3.45 and CHF 4.10. A sustained move above CHF 4.10 could invite momentum flows, while dips toward CHF 3.45 may test buyer interest.

Short-term traders may prefer confirmation on a breakout above resistance with volume. Longer-term investors could scale in on weakness if they believe in 2026 execution. Clear stops and position sizing are prudent, given continuing losses and guidance uncertainty. This is not investment advice; consider personal risk and time horizon.

Final Thoughts

Idorsia stock steadied after FY2025 results that doubled revenue to CHF 221m and cut losses, anchored by Quviviq sales of CHF 134m. The new phase is about execution. Management’s 2026 plan targets CHF 200m in Quviviq sales while still expecting an operating loss of about CHF -160m as restructuring continues. For Swiss investors, the watchlist is simple: quarterly prescription trends, pricing and access updates, and proof that cost cuts do not slow growth. Technicals are neutral, so headlines may drive swings. A disciplined plan, regular review of results, and careful position sizing can help manage risk while the company works toward a more durable path.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.